Boston Scientific Corporation (BSX) is featured among the
best medical device stocks to buy. Its
solid earnings have been noted, and it has received
ratings upgrades. There's news of
insider selling but also a disclosure of a
senior leadership transition with CFO Dan Brennan's retirement and Jon Monson's succession. Q1 2025 earnings showcased
strong growth, and the stock's
low volatility,
safe use of debt, and
innovative position in the healthcare sector strengthen its appeal. BSX has completed a
€1.5 billion offering of senior notes and announced acquiring
SoniVie Ltd. as well as revealing
investor conference schedules. Stock performance has fluctuated, with mentions of declines but also suggestions the medical device maker
outperforms healthcare sector. Boston Scientific's
Q4 2024 earnings calls highlighted record revenue growth, and the corporation's shares have displayed
optimistic performance. As the company continues to steer towards growth and expansion, it remains a strong contender for investment. Among recent milestones and updates, Boston Scientific announced an
agreement to acquire Intera Oncology® Inc, and Cortex, Inc, reinforcing a strategy focused on acquisitions to spur growth.
Boston Scientific Corp BSX News Analytics from Wed, 23 Oct 2024 07:00:00 GMT to Fri, 09 May 2025 14:23:26 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 3
